<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324647</url>
  </required_header>
  <id_info>
    <org_study_id>UGroningen</org_study_id>
    <secondary_id>4799</secondary_id>
    <nct_id>NCT02324647</nct_id>
  </id_info>
  <brief_title>Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield</brief_title>
  <acronym>SERENDIPITY</acronym>
  <official_title>Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martini Hospital Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diakonessenhuis, Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haga Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kennemer Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maxima Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Centre Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meander Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tergooi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vlietland Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scheper Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flevo Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical
      biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the
      presence of hormonal hypersecretion or adrenocortical carcinoma (ACC), respectively. The
      overall aim of this study is to improve the cost-effectiveness of the diagnostic strategy for
      AI. Cost-effectiveness of urine steroid profiling (USP) will be compared to the standard
      diagnostic strategy of repeated CT-imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical
      biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the
      presence of hormonal hypersecretion or adrenocortical carcinoma (ACC),respectively. With
      respect to the diagnosis of ACC, the health benefits of this strategy are controversial for
      the following reasons: a. critical appraisal of literature has revealed a much lower ACC
      frequency of 1.9% than previously presumed; b. CT sensitivity and specificity are suboptimal;
      c. risk of unnecessary adrenalectomies; d. exposure to ionising radiation; e. risk of CT
      contrast reactions (nephropathy, allergic reaction); f. health care related and economical
      costs. The hypothesis to be tested is that incorporation of a single baseline urinary steroid
      profiling (USP) into the management algorithm of AI is more cost-effective than a strategy
      solely based on repeat CT-scanning.

      Objective: SERENDIPITY aims to improve the cost-effectiveness of the diagnostic strategy for
      AI by the application of a single baseline USP. In addition, we aim to examine the
      psychological impact for patients with AI being currently subjected to repeated laboratory
      tests and CT-scanning during several years.

      Study design: This is a prospective observational multicenter study. Study population:
      Patients are eligible if they meet the following inclusion criteria: adrenal mass &gt; 1 cm in
      diameter incidentally discovered during CT or MRI-scanning, performed for reasons other than
      an evaluation for adrenal disease and age 18 years or older. The exclusion criteria are:
      extra-adrenal malignancy (i.e. active or past medical history of malignancy, except for basal
      cell carcinoma), radiologic diagnosis of simple cyst or bilateral adrenal masses, allergy to
      radiocontrast, renal insufficiency (i.e. eGFR &lt; 30 ml/min/1.73m2), pregnancy or inability to
      understand written Dutch.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>2 years</time_frame>
    <description>difference in cost-effectiveness of the current management strategy based on repeat CT-scanning to detect ACC among patients with an AI compared with a strategy using a single baseline USP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of ACC among patients with AI at baseline or during follow-up</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of the percentage of AI that meets the criteria of a malignant CT- phenotype at baseline or during follow-up</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of pathologic diagnosis in surgically removed adrenal glands</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL in patients with an AI at baseline and during follow-up</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency distribution between hormonal hypersecreting and non-functional AI</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conversion rate from non-functioning AI towards a hypersecreting AI during follow-up</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs of diagnostic procedures and surgical interventions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Adrenal Incidentaloma</condition>
  <condition>Adrenocortical Carcinoma</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine samples and serum or plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The research population consists of adult patients with a recently discovered adrenal
        incidentaloma who meet the selection criteria of SERENDIPITY. A total number of 1000
        patients will be included. These subjects will be recruited from the group of patients in
        whom CT/MRI-scanning has been performed with visualization of the adrenal glands (i.e.
        CT/MRI scans of abdomen and/or chest, as the latter often include imaging of the upper
        abdominal region).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  discrete adrenal mass &gt; 1 cm in diameter incidentally discovered during
             CT/MRI-scanning, performed for reasons other than an evaluation for adrenal disease

          -  detection CT/MRI-scan performed ≤ 4 months ago

          -  age 18 years or older.

        Exclusion Criteria:

          -  extra-adrenal malignancy (i.e. active or past medical history of malignancy, except
             for basal cell carcinoma)

          -  radiologic diagnosis of simple cyst or bilateral adrenal masses

          -  allergy to radiocontrast

          -  renal insufficiency (i.e. eGFR &lt; 30 ml/min/1.73m2)

          -  pregnancy

          -  adrenal incidentaloma visible on previous (i.e. &gt; 4 months ago) CT/MRI-scan

          -  inability to understand written Dutch.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiel N Kerstens, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Buitenwerf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P.H.L.T. Bisschop, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E.M.W. Eekhoff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Free University UMC Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E.P.M. van der Kleij-Corssmit, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R.A. Feelders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B. Havekes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H.J.L.M Timmers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G.D. Valk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P.H.N. Oomen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Leeuwarden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K.M. van Tol, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martini Hospital Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R.S.M.E. Wouters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scheper Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A.A.M. Franken, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.R. Meinardi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canisius-Wilhelmina Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. GrooteVeldman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medisch Spectrum Twente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P.C. Oldenburg-Ligtenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meander Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A.F. Muller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diakonessenhuis, Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M.O. van Aken, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haga Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. de Ronde, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kennemer Gasthuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H.R. Haak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Máxima Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. Simsek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Alkmaar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I.M.M.J. Wakelkamp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I.I.L. Berk-Planken, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vlietland Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P.S. van Dam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze Lieve Vrouwe Gasthuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. de Boer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.J.J. de Sonnaville, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tergooi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. Donga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.Elisabeth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N. Smit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flevoland Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michiel N Kerstens, MD, PhD</last_name>
    <phone>0031-503613518</phone>
    <email>m.n.kerstens@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M N Kerstens, MD, PhD</last_name>
      <phone>0031-503613518</phone>
      <email>m.n.kerstens@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS. Management of the clinically inapparent adrenal mass (&quot;incidentaloma&quot;). Ann Intern Med. 2003 Mar 4;138(5):424-9.</citation>
    <PMID>12614096</PMID>
  </reference>
  <reference>
    <citation>Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007 Feb 8;356(6):601-10. Review.</citation>
    <PMID>17287480</PMID>
  </reference>
  <reference>
    <citation>Nawar R, Aron D. Adrenal incidentalomas -- a continuing management dilemma. Endocr Relat Cancer. 2005 Sep;12(3):585-98. Review.</citation>
    <PMID>16172193</PMID>
  </reference>
  <reference>
    <citation>Kievit J, Haak HR. Diagnosis and treatment of adrenal incidentaloma. A cost-effectiveness analysis. Endocrinol Metab Clin North Am. 2000 Mar;29(1):69-90, viii-ix. Review.</citation>
    <PMID>10732265</PMID>
  </reference>
  <reference>
    <citation>Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009 Oct;161(4):513-27. doi: 10.1530/EJE-09-0234. Epub 2009 May 13.</citation>
    <PMID>19439510</PMID>
  </reference>
  <reference>
    <citation>Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics. 2009 Sep-Oct;29(5):1333-51. doi: 10.1148/rg.295095027. Review.</citation>
    <PMID>19755599</PMID>
  </reference>
  <reference>
    <citation>Wolthers BG, Kraan GP. Clinical applications of gas chromatography and gas chromatography-mass spectrometry of steroids. J Chromatogr A. 1999 May 28;843(1-2):247-74. Review.</citation>
    <PMID>10399855</PMID>
  </reference>
  <reference>
    <citation>Gröndal S, Eriksson B, Hagenäs L, Werner S, Curstedt T. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh). 1990 May;122(5):656-63.</citation>
    <PMID>2141212</PMID>
  </reference>
  <reference>
    <citation>Khorram-Manesh A, Ahlman H, Jansson S, Wängberg B, Nilsson O, Jakobsson CE, Eliasson B, Lindstedt S, Tisell LE. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg. 1998 Jun;22(6):605-11; discussion 611-2.</citation>
    <PMID>9597936</PMID>
  </reference>
  <reference>
    <citation>Kikuchi E, Yanaihara H, Nakashima J, Homma K, Ohigashi T, Asakura H, Tachibana M, Shibata H, Saruta T, Murai M. Urinary steroid profile in adrenocortical tumors. Biomed Pharmacother. 2000 Jun;54 Suppl 1:194s-197s.</citation>
    <PMID>10915023</PMID>
  </reference>
  <reference>
    <citation>Minowada S, Kinoshita K, Hara M, Isurugi K, Uchikawa T, Niijima T. Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. Endocrinol Jpn. 1985 Feb;32(1):29-37.</citation>
    <PMID>4017973</PMID>
  </reference>
  <reference>
    <citation>Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002 Mar;21(2):271-92.</citation>
    <PMID>11939242</PMID>
  </reference>
  <reference>
    <citation>Arnaldi G, Boscaro M. Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):405-19. doi: 10.1016/j.beem.2011.12.006. Epub 2012 May 22. Review.</citation>
    <PMID>22863384</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Michiel N. Kerstens</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Urinary steroid profiling</keyword>
  <keyword>Adrenal incidentaloma</keyword>
  <keyword>Adrenocortical carcinoma</keyword>
  <keyword>cost-effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
    <mesh_term>Adrenocortical Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

